5-苄氧基吲哚-3-乙酰胺 | 5933-28-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 5-苄氧基吲哚-3-乙酰胺
• 中文别名: 5-苄氧基吲哚-3-乙胺
• 英文名称: 5-benzyloxyindole-3-acetamide
• 英文别名: (5-benzyloxy-indol-3-yl)-acetic acid amide；(5-Benzyloxy-indol-3-yl)-essigsaeure-amid；2-(5-(Benzyloxy)-1H-indol-3-yl)acetamide；2-(5-phenylmethoxy-1H-indol-3-yl)acetamide
• CAS: 5933-28-8
• 化学式: C₁₇H₁₆N₂O₂
• 分子量: 280.326
• InChiKey: IKDKEVWKCASVEF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  68.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-苄氧基吲哚-3-乙酰胺 在 甲醇 、 lithium aluminium tetrahydride 、 platinum on activated charcoal 、 乙醚 作用下， 生成 5-羟基色胺
  参考文献：
  名称：

  THE SYNTHESIS OF 5-HYDROXYTRYPTAMINE

  摘要：

  DOI：

  10.1021/ja01154a551
• 作为产物：
  描述：

  5-苄氧基吲哚 在 1,4-二氧六环 、 乙醇 、 氰化钠 、 溶剂黄146 作用下， 生成 5-苄氧基吲哚-3-乙酰胺
  参考文献：
  名称：

  The Synthesis of Labile Hydroxytryptophan Metabolites¹

  摘要：

  DOI：

  10.1021/ja01651a001

文献信息

• Neuroprotective and anti-proliferative compounds
  申请人：——

  公开号：US20040102467A1

  公开（公告）日：2004-05-27

  This invention features ring-substituted pyrrolo-&bgr;-carboline derivatives and ring-substitution and structural derivatives of 3-(1H-indol-3-yl)-1H-pyrrole-2,5-dione of formulas (I-III), which are useful as neuroprotective and anti-proliferative compounds. Also disclosed are methods for the preparation of these compounds, selected biological profiles and uses of these compounds in the treatment of various neurodegenerative and inflammatory diseases of the human nervous system and in the treatment of various other proliferative disorders characterized by loss of growth or cellular differentiation control including, but not limited to, cancer and inflammation. 1

  这项发明涉及环取代吡咯β-咔啉衍生物和3-(1H-吲哚-3-基)-1H-吡咯-2,5-二酮的环取代和结构衍生物，其作为神经保护和抗增殖化合物具有用途。还公开了这些化合物的制备方法，选择的生物学特性以及这些化合物在治疗人类神经系统的各种神经退行性和炎症性疾病以及治疗其他各种增殖性疾病中的用途，这些疾病的特征是失去生长或细胞分化控制，包括但不限于癌症和炎症。
• Brain-specific drug delivery
  申请人：University of Florida

  公开号：US04824850A1

  公开（公告）日：1989-04-25

  The subject compounds, which are adapted for the site-specific/sustained delivery of centrally acting drug species to the brain, are: (a) compounds of the formula [D--DHC] (I) wherein [D] is a centrally acting drug species, and [DHC] is the reduced, biooxidizable, blood-brain barrier penetrating lipoidal form of a dihydropyridine.revreaction.pyridinium salt redox carrier, with the proviso that when [DHC] is ##STR1## wherein R is lower alkyl or benzyl and [D] is a drug species containing a single NH.sub.2 or OH functional group, the single OH group when present being a primary or secondary OH group, said drug species being linked directly through said NH.sub.2 or OH function group to the carbonyl function of [DHC], then [D] must be other than a sympathetic stimulant, steroid sex hormone or long chain alkanol; and (b) non-toxic pharmaceutically acceptable salts of compounds of formula (I) wherein [D] is a centrally acting drug species and [DHC] is the reduced, biooxidizable, blood-brain barrier penetrating lipoidal form of a dihydropyridine.revreaction.pyridinium salt redox carrier. The corresponding ionic pyridinium salt type drug/carrier entitles [D--QC].sup.+ X.sup.- are also disclosed.

  这些适用于将中枢作用药物种类定向/持续释放到大脑的主体化合物是：(a) 公式[D--DHC] (I)的化合物，其中[D]是中枢作用药物种类，[DHC]是二氢吡啶盐氧化还原、穿透血脑屏障的脂质形式，带有二氢吡啶盐氧化还原载体，但当[DHC]是##STR1##其中R是较低的烷基或苄基，[D]是含有单个NH.sub.2或OH官能团的药物种类，当存在单个OH官能团时，该OH官能团为一次或二次OH官能团，该药物种类通过NH.sub.2或OH官能团直接连接到[DHC]的羰基官能团，则[D]不能是交感神经刺激剂、类固醇性激素或长链烷醇；以及(b) 公式(I)的化合物的无毒的药用可接受盐，其中[D]是中枢作用药物种类，[DHC]是二氢吡啶盐氧化还原、穿透血脑屏障的脂质形式，带有二氢吡啶盐氧化还原载体。还披露了相应的离子式吡啶盐型药物/载体[D--QC].sup.+ X.sup.-。
• Use of indole compounds for fat reduction and skin and soft tissue tightening
  申请人：Alevere Medical Corporation

  公开号：US10258605B2

  公开（公告）日：2019-04-16

  The present invention relates to indole compounds and compositions and uses thereof, including uses of the indole compounds and compositions for the reduction or removal of localized fat deposits and/or tightening of skin and soft tissue laxity in subjects. The indole compounds can be employed, for example, in the cosmetic sector or for producing pharmaceutical products.

  本发明涉及吲哚化合物和组合物及其用途，包括吲哚化合物和组合物用于减少或去除局部脂肪沉积和/或收紧受试者的皮肤和软组织松弛。例如，吲哚化合物可用于化妆品行业或生产医药产品。
• Nenitzescu; Raileanu, Chemische Berichte, 1958, vol. 91, p. 1141,1143
  作者：Nenitzescu、Raileanu

  DOI：——

  日期：——
• Process for producing 5-hydroxytryptamine
  申请人：ABBOTT LAB

  公开号：US02715129A1

  公开（公告）日：1955-08-09